TopFunds

Bio-Techne

NASDAQ: TECH

Stock price

72.71 USD

(+0%) TODAY

Life Sciences Tools & ServicesBiotechnology
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
0.7
0.5
0.8
0.6
1.5
0.9
1.7
1.8
1.1
0.5
1.2
5.2%
02Free cash flow per share
0.9
0.9
1
1
1
1.9
1.7
1.3
1.5
1.6
1.7
7%
03Dividends per share
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
-
04Dividends payout, %
45.6%
61.2%
38.3%
50.3%
21.3%
35.3%
18.5%
17.6%
30%
68.7%
27.5%
(4.9)%
PROFIT AND LOSS STATEMENT
05Revenue
$ 499
$ 563
$ 643
$ 714
$ 738.7
$ 931
$ 1,106
$ 1,137
$ 1,159
$ 1,220
$ 1,215
9.3%
06% Change
10.3%
12.8%
14.2%
11%
3.5%
26%
18.8%
2.8%
2%
5.2%
(0.4)%
9.3%
07Cost of revenue
(162.4)
(188.5)
(210.8)
(240.5)
(255.5)
(298.2)
(349.1)
(366.9)
(389.3)
(429.4)
(416)
9.9%
08Gross profit
336.7
374.5
432.1
473.5
483.2
632.9
756.5
769.8
769.7
790.3
799.1
9%
09% Margin
67.5%
66.5%
67.2%
66.3%
65.4%
68%
68.4%
67.7%
66.4%
64.8%
65.8%
66.7% A
10Operating expenses
(186.1)
(252.8)
(296)
(326.8)
(325.8)
(395.6)
(459.9)
(470.9)
(563)
(688)
(547.2)
11.4%
11% of Revenue
(37.3)%
(44.9)%
(46)%
(45.8)%
(44.1)%
(42.5)%
(41.6)%
(41.4)%
(48.6)%
(56.4)%
(45)%
(44.9)% A
12Operating Income
150.6
121.8
136.2
125.6
157.4
237.3
296.6
298.9
206.7
102.3
251.9
5.3%
13Income tax expense
(43)
(35.9)
(0.6)
(15.9)
(47.2)
(8.6)
(38.3)
(53.2)
(17.6)
(25.1)
(58.8)
3.2%
14Net Income
104.5
77.3
125.4
96.1
229.3
140.4
272.1
285.3
168.1
73.4
181.9
5.7%
15% Margin
20.9%
13.7%
19.5%
13.5%
31%
15.1%
24.6%
25.1%
14.5%
6%
15%
18.1% A
16Shares Outstanding
149,304
150,000
152,220
155,568
157,604
161,932
164,116
161,855
160,774
159,717
157,009
0.5%
17EPS Basic
0.7
0.5
0.8
0.6
1.5
0.9
1.7
1.8
1.1
0.5
1.2
5.3%
18EPS Diluted
0.7
0.5
0.8
0.6
1.5
0.9
1.7
1.8
1.1
0.5
1.2
5.2%
19EBITDA
192
179.4
200.6
211.9
378.4
249.9
413.8
457.1
313.1
216.9
343.4
6%
% Margin
38.5%
31.9%
31.2%
29.7%
51.2%
26.8%
37.4%
40.2%
27%
17.8%
28.3%
32.7% A
20Net Interest Income (expense)
(1.5)
(7.1)
(9.8)
(21.1)
(18.6)
(13.5)
(10.5)
(7.8)
(12.4)
(4.6)
(5.4)
13.7%
21Net Debt / EBITDA
0.4
1.4
1.1
1.9
0.8
0.9
0.4
0.6
0.9
1.3
0.1
0.9 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
64.2
91.6
122
100.9
146.6
199.1
172.6
180.6
151.8
162.2
264.7
15.2%
23Short-term investments
31.6
66.1
59.8
65.1
124.3
32.5
74.5
23.7
1.1
-
-
-
24Accounts receivable
93.4
116.8
120.3
137.5
122.5
145.4
194.5
218.5
241.4
206.9
220.5
9%
25Other current assets
7.6
13.3
10.7
18.1
24.3
16.9
22.9
27.1
43.4
49.8
63.4
23.7%
26Inventory
57.1
60.2
85.6
91.1
103.2
116.7
141.1
171.6
179.7
189.4
195.7
13.1%
27Total Current Assets
253.9
345.3
398.4
412.6
520.9
510.6
605.6
621.5
617.4
608.3
744.4
11.4%
Non-Current Assets
28Net property, plant & equipment
132.4
135.1
145.3
154
248.3
281.7
288.8
324.5
342.4
319.1
299.2
8.5%
29Long-term investments
(62.8)
40.4
2.7
(89.8)
-
-
-
255.9
242.3
251
253.4
-
30Other non-current assets
806.1
1,036
1,047
1,408
1,258
1,471
1,401
1,437
1,502
1,380
1,382
5.5%
31Total Non-Current Assets
875.6
1,211
1,195
1,472
1,507
1,752
1,689
2,017
2,086
1,950
1,935
8.3%
Total Assets
1,130
1,557
1,593
1,884
2,028
2,263
2,295
2,639
2,704
2,558
2,679
9%
LIABILITIES
Current Liabilities
32Accounts payable
20.7
16.9
18.5
16.2
23.1
29.4
33.9
25.7
38
25.3
26.7
2.6%
33Short-term debt
3.8
-
-
12.5
22
24.1
24.4
11.2
12.9
14.1
14.9
14.8%
34Other current liabilities
29.7
118.5
60.2
73.3
61.5
98.8
117.7
91.6
108.5
136.4
122.1
15.2%
35Total Current Liabilities
54.1
135.4
78.7
102
106.7
152.3
176
128.5
159.4
175.8
163.7
11.7%
Non-Current Liabilities
36Long-term debt
91.5
343.8
339
492.7
411.5
396.5
301.5
443.8
406.6
430
274.2
11.6%
37Other non-current liabilities
104.6
126.7
96.4
124.2
128.2
143
116.2
99.9
69
33.3
132.9
2.4%
38Total Non-Current Liabilities
196.1
470.5
435.4
616.8
539.7
539.4
417.8
543.7
475.6
463.2
407.1
7.6%
39Total Liabilities
250.2
605.8
514.1
718.8
646.4
691.7
593.8
672.2
635
639.1
570.8
8.6%
SHAREHOLDERS` EQUITY
40Common stock
0.4
0.4
0.4
0.4
0.4
0.4
1.6
1.6
1.6
1.6
1.6
15.4%
41Retained earnings / (deficit)
770.6
799
876.9
931.9
1,058
1,086
1,123
1,310
1,325
1,066
1,144
4%
42Accumulated other comprehensive income / (loss)
(70.4)
(48.9)
(44.8)
(83.5)
(97.2)
(57.3)
(75.2)
(66.1)
(78.3)
(59.9)
(70.6)
-
43Noncontrolling interests
-
-
-
-
-
8.3
(0.8)
-
-
-
-
-
44Total shareholders' equity
879.3
950.8
1,079
1,166
1,381
1,571
1,701
1,967
2,069
1,919
2,108
9.1%
45Total Liabilities and shareholders' Equity
1,130
1,557
1,593
1,884
2,028
2,263
2,295
2,639
2,704
2,558
2,679
9%
46Total Debt
133.8
349.9
339
505.2
433.5
420.6
326
455
419.5
444.1
289.1
8%
47Net Debt
69.5
258.3
217
404.3
286.9
221.5
153.4
274.4
267.7
281.9
24.4
(10)%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
104.5
77.3
125.4
96.1
229.3
140.4
272.1
285.3
168.1
73.4
181.9
5.7%
49Depreciation & amortization
42.8
60
64.5
78.2
82.7
87.7
101.1
107.2
111.7
109.9
97.4
8.6%
50Share-based compensation expense
9.4
14.6
28.2
32.3
32.4
49
42.2
39.2
38
40.8
41.4
15.9%
51Changes in working capital and other assets
(12.8)
(8.5)
(47.7)
(24.9)
(139.2)
75
(90)
(177.3)
(18.9)
63.4
(28.5)
8.3%
52Net cash flows from operating activities
143.9
143.4
170.4
181.6
205.2
352.2
325.3
254.4
299
287.6
292.1
7.3%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(16.9)
(15.2)
(20.9)
(25.4)
(51.7)
(44.3)
(44.9)
(38.2)
(62.9)
(31)
(28.8)
5.5%
54Purchases of investments / marketable securities
-
(3.1)
(8.6)
(43.5)
(70.2)
(39.7)
(25)
(20.5)
(5.5)
(5.5)
-
-
55Proceeds from maturities of marketable securities
0.8
6.1
36.4
21.6
147.1
66.4
26.1
108.5
28.1
1.1
6
22.8%
56Other investing activities
(91.4)
(293.8)
(45.6)
(289.5)
1.9
(225.9)
(53)
(315.4)
(162.7)
0.3
4.6
-
57Net cash flows from investing activities
(107.6)
(306)
(38.7)
(336.8)
27.1
(243.5)
(96.9)
(265.6)
(203)
(35.2)
(18.2)
(16.3)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
5.5
5.3
19.2
(15.4)
(50.1)
(43.2)
(160.9)
(19.6)
(80)
(275.7)
38.9
21.7%
59Dividends paid, net
(47.6)
(47.3)
(48)
(48.4)
(48.9)
(49.6)
(50.2)
(50.3)
(50.4)
(50.4)
(49.9)
0.5%
60Debt issuance (repayments), net
18.5
252
(4.5)
166.5
(148.5)
(15.5)
(85.5)
94
(31)
27
(146)
-
61Other financing activities
0.6
(20.5)
(65.9)
31.7
63.7
45.7
53.8
(1.5)
39.1
45.2
(12.1)
-
62Net cash flows from financing activities
(23.1)
189.4
(99.2)
134.4
(183.8)
(62.6)
(242.9)
22.6
(122.4)
(253.9)
(169.1)
22%
63Increase (decrease) in cash and cash equivalents
9.7
27.4
30.4
(21.1)
45.7
52.5
(26.5)
8
(28.8)
10.4
102.5
26.6%
64Cash and equivalents, ending balance
64.2
91.6
122
100.9
146.6
199.1
172.6
180.6
151.8
162.2
264.7
15.2%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
127
128.3
149.4
156.2
153.5
307.9
280.4
216.1
236.1
256.6
263.2
7.6%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
20262025202420232022202120202019201820172016

Bio-Techne (TECH) financial statements and performance

Explore Bio-Techne (TECH) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.